Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
169 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10 Therapeutics Development 11 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16 Late Stage Products 16 Early Stage Products 17 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32 Assessment by Monotherapy/Combination Products 32 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39 AB Science SA 39 Advenchen Laboratories, LLC 41 Amgen Inc. 42 ArQule, Inc. 43 Ascendis Pharma A/S 44 Astellas Pharma Inc. 45 AstraZeneca Plc 46 AVEO Pharmaceuticals, Inc. 47 Bayer AG 48 Boehringer Ingelheim GmbH 49 Bristol-Myers Squibb Company 50 CASI Pharmaceuticals Inc. 51 Celon Pharma Sp. z o.o. 52 Debiopharm International SA 53 Eddingpharm 54 Eisai Co., Ltd. 55 Eli Lilly and Company 57 Hutchison MediPharma Limited 58 Incyte Corporation 59 Johnson & Johnson 60 Les Laboratoires Servier SAS 61 Merck KGaA 62 Novartis AG 63 Principia Biopharma Inc. 64 Vichem Chemie Research Ltd. 65 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 66 ARQ-087 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 ASP-5878 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 AV-370 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 AZD-4547 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 B-701 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 BAY-1163877 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 BMS-986036 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 CPL-043 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Debio-1347 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 E-7090 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 EDP-317 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 ENMD-2076 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 erdafitinib - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 HMPL-453 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 INCB-54828 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 infigratinib - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 lenvatinib mesylate - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 lucitanib - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 LY-2874455 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 masitinib - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 nintedanib - Drug Profile 121 Product Description 121 Mechanism Of Action 121 R&D Progress 121 pazopanib hydrochloride - Drug Profile 130 Product Description 130 Mechanism Of Action 130 R&D Progress 130 pazopanib hydrochloride + pembrolizumab - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 PRN-1371 - Drug Profile 138 Product Description 138 Mechanism Of Action 138 R&D Progress 138 Recombinant Peptide to Antagonize FGFR3 for Achondroplasia - Drug Profile 139 Product Description 139 Mechanism Of Action 139 R&D Progress 139 Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 140 Product Description 140 Mechanism Of Action 140 R&D Progress 140 Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 141 Product Description 141 Mechanism Of Action 141 R&D Progress 141 S-49076 - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 sprifermin - Drug Profile 144 Product Description 144 Mechanism Of Action 144 R&D Progress 144 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 146 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 151 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 153 Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 153 Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 153 Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 154 Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 156 Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 157 Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 159 Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 159 Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 160 Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 162 Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 163 Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 164 Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 165 Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 165 Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 166 Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 167 Appendix 168 Methodology 168 Coverage 168 Secondary Research 168 Primary Research 168 Expert Panel Validation 168 Contact Us 168 Disclaimer 169
List of Tables
Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Number of Products under Development by Companies, H2 2016 18 Number of Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Development by Companies, H2 2016 (Contd..2) 22 Products under Development by Companies, H2 2016 (Contd..3) 23 Products under Development by Companies, H2 2016 (Contd..4) 24 Products under Development by Companies, H2 2016 (Contd..5) 25 Products under Development by Companies, H2 2016 (Contd..6) 26 Products under Development by Companies, H2 2016 (Contd..7) 27 Products under Development by Companies, H2 2016 (Contd..8) 28 Products under Development by Companies, H2 2016 (Contd..9) 29 Number of Products under Investigation by Universities/Institutes, H2 2016 30 Products under Investigation by Universities/Institutes, H2 2016 31 Assessment by Monotherapy/Combination Products, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Pipeline by AB Science SA, H2 2016 39 Pipeline by Advenchen Laboratories, LLC, H2 2016 41 Pipeline by Amgen Inc., H2 2016 42 Pipeline by ArQule, Inc., H2 2016 43 Pipeline by Ascendis Pharma A/S, H2 2016 44 Pipeline by Astellas Pharma Inc., H2 2016 45 Pipeline by AstraZeneca Plc, H2 2016 46 Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 47 Pipeline by Bayer AG, H2 2016 48 Pipeline by Boehringer Ingelheim GmbH, H2 2016 49 Pipeline by Bristol-Myers Squibb Company, H2 2016 50 Pipeline by CASI Pharmaceuticals Inc., H2 2016 51 Pipeline by Celon Pharma Sp. z o.o., H2 2016 52 Pipeline by Debiopharm International SA, H2 2016 53 Pipeline by Eddingpharm, H2 2016 54 Pipeline by Eisai Co., Ltd., H2 2016 55 Pipeline by Eli Lilly and Company, H2 2016 57 Pipeline by Hutchison MediPharma Limited, H2 2016 58 Pipeline by Incyte Corporation, H2 2016 59 Pipeline by Johnson & Johnson, H2 2016 60 Pipeline by Les Laboratoires Servier SAS, H2 2016 61 Pipeline by Merck KGaA, H2 2016 62 Pipeline by Novartis AG, H2 2016 63 Pipeline by Principia Biopharma Inc., H2 2016 64 Pipeline by Vichem Chemie Research Ltd., H2 2016 65 Dormant Projects, H2 2016 146 Dormant Projects (Contd..1), H2 2016 147 Dormant Projects (Contd..2), H2 2016 148 Dormant Projects (Contd..3), H2 2016 149 Dormant Projects (Contd..4), H2 2016 150 Discontinued Products, H2 2016 151 Discontinued Products (Contd..1), H2 2016 152
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
